Oxford Biomedica (LON:OXB) Stock Crosses Below 200-Day Moving Average – Here’s Why

Oxford Biomedica plc (LON:OXB) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 664.67 and traded as low as GBX 600. Oxford Biomedica shares last traded at GBX 603.19, with a volume of 228,335 shares trading hands.

Wall Street Analysts Forecast Growth

OXB has been the subject of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Royal Bank Of Canada lowered their target price on shares of Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a report on Wednesday, June 24th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Oxford Biomedica presently has an average rating of “Buy” and a consensus price target of GBX 633.38.

Oxford Biomedica Stock Down 0.5%

The company has a market cap of £726.22 million, a price-to-earnings ratio of -22.29 and a beta of 1.12. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The firm’s 50-day moving average price is GBX 615.15 and its 200-day moving average price is GBX 664.67.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.